Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Overview: A Deep Dive into Financials and Developments

Core Insights - Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics, focusing on treatments for rare diseases and cardiovascular conditions [1][6] - The company's revenue growth is driven by a diverse product lineup, including key drugs like Amvuttra, Givlaari, and Oxlumo [1][6] - Alnylam is conducting the ZENITH global Phase 3 trial for zilebesiran to advance its cardiovascular research [1] Financial Performance - In the first half of 2025, Alnylam's rare disease drugs generated $236.8 million in revenues, marking a 16% increase from the previous year [4] - The company has a negative price-to-earnings (P/E) ratio of -185.46 and a high debt-to-equity ratio of 5.18, indicating financial challenges [4][6] - Despite these challenges, Alnylam's current ratio of 2.80 suggests a strong ability to cover short-term liabilities [5][6] Product Development - Amvuttra has received approval in the U.S. and EU for treating polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis and ATTR amyloidosis with cardiomyopathy (ATTR-CM) [3] - The success of Amvuttra is attributed to new patient initiations and transitions from Onpattro, Alnylam's first FDA-approved drug for hATTR amyloidosis [3]